Clinical Trial: Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07626281) titled 'Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation' on May 29.

Brief Summary: The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a single 284 mg subcutaneous (SC) administration.

Study Start Date: June 15

Study Type: INTERVENTIONAL

Condition: Inclisiran Formulation

Intervention: DRUG: Inclisiran formulation containing PS80

Inc...